Press Release: Sanofi and Regenerons Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine…
Press Release: Sanofis Board of Directors proposes the appointment of Christel Heydemann as an independent director
Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director …
Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season
Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants…
Press Release: Sanofis Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease
Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic…
Press Release: Sanofi and Regenerons Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to…
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha…
Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment…
Press release: Availability of the Q3 2025 Aide mmoire
Availability of the Q3 2025 Aide mémoire Paris, France – September 24,…
Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range
Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is…
Press Release: Sanofis Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly…
